WilmerHale advised EQRx, Inc., a Cambridge-based biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society, in a global strategic partnership with CStone Pharmaceuticals, a China-based based biopharmaceutical company. Under the terms of the agreement, EQRx will license ex-Greater China rights for two key late-stage immuno-oncology antibodies, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), allowing them to be competitively positioned in global markets against established treatments for the target indications. EQRx will obtain exclusive rights to lead global development and commercialization of the antibodies worldwide, excluding Mainland China, Taiwan, Hong Kong and Macau. The deal is expected to close in November 2020, subject to the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
The WilmerHale team representing EQRx was led by Jenna Ventorino and included Victoria Hartmann, Steve Singer, Colleen Superko, Wenli Gu, Edward Sharon and Julie Hogan-Rodgers.